Investor Presentation

Thyrocare delivered a strong quarter. **Business Performance:** Consolidated revenue grew 22% YoY to ₹216.53 Cr, fueled by pathology revenue rising 24%. Franchisee revenue climbed 20% to ₹125 Cr, and partnership revenue jumped 35% to ₹66 Cr.

The company processed 5.33 crore tests, a 21% YoY increase, serving 5 million patients.

Active franchisees expanded 20% to over 10,100. Quality remains robust, with 96% of samples processed in NABL labs. **Growth Drivers or Strategy:** The company is focusing on deeper penetration into India with a targeted test menu, strengthening its franchise network, and broadening partnerships, including insurance and home ECG services.

International expansion in Tanzania is also a key priority, driven by a B2B, affordable value-driven model. **Recent Developments:** Thyrocare launched a new Regional Processing Lab in Vijayawada, Andhra Pradesh, enhancing its Southern India network.

It also held advisory board and channel partner meets to boost relationships and was certified as a 'Great Place To Work.' **Key Financial Metrics:** Consolidated Reported EBITDA surged 48% YoY to ₹71.45 Cr, with Normalized EBITDA at 35%. Profit After Tax (PAT) soared 82% YoY to ₹47.90 Cr. **Management Commentary / Outlook:** Management aims to make quality diagnostics affordable for all, reinforcing its strategy as a B2B service provider focused on accessible, high-quality testing.